These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33956350)

  • 21. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy.
    Fasulo V; Cowan JE; Maggi M; Washington SL; Nguyen HG; Shinohara K; Lazzeri M; Casale P; Carroll PR
    Eur Urol Oncol; 2022 Feb; 5(1):61-69. PubMed ID: 33069628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
    Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
    Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
    Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
    [No Abstract]   [Full Text] [Related]  

  • 26. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
    Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
    Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance.
    Helfand BT; Xu J
    Urol Clin North Am; 2021 Aug; 48(3):401-409. PubMed ID: 34210494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.
    Erickson AM; Luzzago S; Semjonow A; Vasarainen H; Laajala TD; Musi G; de Cobelli O; Mirtti T; Rannikko A
    Eur Urol Oncol; 2018 Sep; 1(4):268-275. PubMed ID: 31100247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
    Pepe P; Garufi A; Priolo G; Pennisi M
    World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia.
    Shah RB; Li J; Dhanani N; Mendrinos S
    Urol Oncol; 2016 Mar; 34(3):120.e1-7. PubMed ID: 26585946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
    Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.
    Cussenot O; Cornu JN; Drouin SJ; Mozer P; Egrot C; Vaessen C; Haab F; Bitker MO; Rouprêt M
    World J Urol; 2014 Apr; 32(2):545-50. PubMed ID: 24166289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
    Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
    Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
    Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
    World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection rate for significant cancer at confirmatory biopsy in men enrolled in Active Surveillance protocol: 20 cores vs 30 cores vs MRI/TRUS fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Barbera M; Panella P; Pennisi M; Morgia G
    Arch Ital Urol Androl; 2016 Dec; 88(4):300-303. PubMed ID: 28073197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.